Preliminary data from the recurrent glioblastoma trial suggested that treatment with marizomib might be particularly beneficial in the subgroup of patients with MGMT promoter-unmethylated tumors.18 OS in patients with MGMT promoter-unmethylated tumors in the ITT population (ITT/uMGMT) was not statistically different (median 15.1 months (95% CI, 13.4–15.7) in the marizomib arm and 14.5 months (95% CI, 13.5–15.7) in the standard arm; stratified HR = 1.13; 95% CI, 0.88–1.44, stratified log-rank: P = .27) (Figure 3A). Here, MGMT is linked to glioblastoma.